Literature DB >> 23288125

Ex vivo lung reconditioning: a new era for lung transplantation.

Alessandro Wasum Mariani1, Paulo Manuel Pêgo-Fernandes, Luis Gustavo Abdalla, Fabio Biscegli Jatene.   

Abstract

Lung transplantation has come to be viewed as the best treatment option for various end-stage lung diseases. The low number of viable donors continues to be a major obstacle to increasing the number of lung transplants, resulting in high mortality among patients on the waiting list. Unlike transplantation of other solid organs, lung transplantation is primarily limited not by the absolute number of donors but by the viability of the donor lungs, which can be damaged by brain death and by treatments given in the ICU. There are various proposals of ways to increase the number of lung donors: intensification of donation campaigns, use of non-heart-beating donors, living lobar lung transplantation, and adoption of more flexible criteria for donors. However, the proposal that has attracted the most attention from lung transplant groups is ex vivo lung perfusion, especially due to the prospect of reconditioning previously discarded lungs. This system consists of perfusion and ventilation of the isolated heart-lung block using a modified cardiopulmonary bypass circuit. Various authors have been studying this technique due to the satisfactory results obtained and the prospect of an increase in the number of organs suitable for transplantation. Researchers in Sweden, Canada, Austria, England, Spain, and Brazil have extensive experience with the method and have introduced modifications to it. The objective of this article was to review the development of, state of the art in, and future prospects for the ex vivo model of lung perfusion and reconditioning.

Entities:  

Mesh:

Year:  2012        PMID: 23288125     DOI: 10.1590/s1806-37132012000600015

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  4 in total

Review 1.  Lung transplantation.

Authors:  José Eduardo Afonso Júnior; Eduardo de Campos Werebe; Rafael Medeiros Carraro; Ricardo Henrique de Oliveira Braga Teixeira; Lucas Matos Fernandes; Luis Gustavo Abdalla; Marcos Naoyuki Samano; Paulo Manuel Pêgo-Fernandes
Journal:  Einstein (Sao Paulo)       Date:  2015 Apr-Jun

2.  Soluble factors of mesenchimal stem cells (FS-MSC) as a potential tool to reduce inflammation in donor's lungs after hypovolemic shock.

Authors:  Vinicius Luderer Dias; Karina Andrighetti de Oliveira Braga; Natalia Aparecida Nepomuceno; Liliane Moreira Ruiz; Juan David Ruiz Perez; Aristides Tadeu Correia; Luiz Carlos de Caires Junior; Ernesto Goulart; Mayana Zatz; Paulo Manuel Pêgo-Fernandes
Journal:  J Bras Pneumol       Date:  2021-08-09       Impact factor: 2.624

Review 3.  Inflammation and Oxidative Stress in the Context of Extracorporeal Cardiac and Pulmonary Support.

Authors:  Sanaz Hatami; Joshua Hefler; Darren H Freed
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

4.  Endothelin receptor antagonist improves donor lung function in an ex vivo perfusion system.

Authors:  K Walweel; K Skeggs; A C Boon; L E See Hoe; M Bouquet; N G Obonyo; S E Pedersen; S D Diab; M R Passmore; K Hyslop; E S Wood; J Reid; S M Colombo; N J Bartnikowski; M A Wells; D Black; L P Pimenta; A K Stevenson; K Bisht; L Marshall; D A Prabhu; L James; D G Platts; P S Macdonald; D C McGiffin; J Y Suen; J F Fraser
Journal:  J Biomed Sci       Date:  2020-10-02       Impact factor: 8.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.